SLU-PP-332 (5 mg Vial) Dosage Protocol

Quickstart Highlights

PRECLINICAL RESEARCH COMPOUND: SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα/β/γ) studied exclusively in murine models for its ability to activate an aerobic-exercise gene program, enhance mitochondrial function, and improve endurance and cardiometabolic phenotypes^[1]^[2]^[3]. No human trials have been conducted as of November 2025. This educational protocol reflects published murine regimens using intraperitoneal administration.

Evidence Base: Preclinical only—in vivo mouse studies with intraperitoneal dosing (25–50 mg/kg twice daily).

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.

Murine dose range: 1250–2500 mcg daily (for a 25 g mouse), administered in two divided doses.

Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.

Storage: Lyophilized: −20 °C (−4 °F); reconstituted: 2–8 °C (35.6–46.4 °F).

Dosing & Reconstitution Guide

Educational guide based on published murine regimens

Murine-Equivalent Protocol (3 mL = ~1.67 mg/mL)

Phase	Daily Dose (mcg)	Per-Injection Dose (mcg)	Units per Injection (mL)
Weeks 1–2	1250 mcg	625 mcg	37.5 units (0.375 mL)
Weeks 3–8	2500 mcg	1250 mcg	75 units (0.75 mL)

Route & Frequency: Published murine studies used intraperitoneal administration twice daily (25–50 mg/kg)^[1]^[2]^[3]. Daily mcg values above are expressed for a 25 g mouse. No reputable sources support once-daily subcutaneous use for this compound.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Critical: This guide reflects preclinical murine research only. This information is for educational and research purposes exclusively—not for human consumption. No human safety or efficacy data exist for SLU-PP-332.

Supplies Needed

Based on an 8–16 week murine-equivalent protocol with twice-daily administration.

Peptide Vials (SLU-PP-332, 5 mg each):

8 weeks ≈ 25 vials
12 weeks ≈ 39 vials
16 weeks ≈ 53 vials

Insulin Syringes (U-100):

Per week: 14 syringes (2/day)
8 weeks: 112 syringes
12 weeks: 168 syringes
16 weeks: 224 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (25 vials): 75 mL → 8 × 10 mL bottles
12 weeks (39 vials): 117 mL → 12 × 10 mL bottles
16 weeks (53 vials): 159 mL → 16 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each administration.

Per week: 28 swabs (4/day)
8 weeks: 224 swabs → recommend 3 × 100-count boxes
12 weeks: 336 swabs → recommend 4 × 100-count boxes
16 weeks: 448 swabs → recommend 5 × 100-count boxes

View Supplier

Protocol Overview

Concise summary of the murine-based regimen.

Evidence Status: Preclinical only—no human trials exist^[1]^[11].

Mechanism: Pan-ERR agonist; activates aerobic-exercise gene program and enhances mitochondrial function.

Published Route: Intraperitoneal administration in mice (25–50 mg/kg twice daily).

Cycle Length: 8 weeks in published studies.

Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL).

Storage: Lyophilized frozen; reconstituted refrigerated.

Research Disclaimer